Tag Archives: Atripla

PLHIVs in Argentina file patent opposition against Gilead/BMS ARV combination Atripla

  Argentina, December 4 , 2013.- For the first time in Argentina organized communities filed a pre-grant opposition against a patent for a combination of antiretrovirals with priority use in the country. A pricing study conducted by RedLAM “Latin American … Continue reading

Posted in Compulsory Licensing, Evergreening, Generics, Hepatitis C, HIV/Aids, IP Rights, IPR Enforcement, Patent examination system, Patents, Post-grant opposition, Pricing, Tuberculosis (TB) | Tagged , , | Leave a comment